New blood tests could spare transplant patients from painful biopsies
NCT ID NCT04855422
First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study is testing two blood tests, AlloSure and AlloMap, to see if they can detect organ rejection in people who have received a combined kidney and pancreas transplant. The goal is to find a less invasive way to monitor for rejection compared to the standard tissue biopsy. The study will follow 42 patients for up to three years after their transplant to see how well the blood tests work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood tests (AlloSure and AlloMap)
- What this could lead to
- If successful, these blood tests could help doctors detect organ rejection earlier and more safely in kidney-pancreas transplant patients, reducing the need for invasive biopsies.
- What could go wrong
- This is a small, early pilot study with only 42 participants. The tests may not prove accurate enough to replace biopsies, and results may not apply to all transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT; COMPLICATION, REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.